FMP
Milestone Pharmaceuticals Inc.
MIST
NASDAQ
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1.8 USD
0.085 (4.72%)
About
ceo
Mr. Joseph G. Oliveto M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
CIK
0001408443
ISIN
CA59935V1076
CUSIP
59935V107
Address
1111 Dr. Frederik-Philips Boul...
Phone
15143360444
Country
CA
Employee
47
IPO Date
May 9, 2019
Key Executives
